Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF OPERATING OFFICER | March 09, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date March 09, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,055 |
Ending reported balance
After 2026-03-10 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-03-09 · Exercise / conversion · Acquired 20,000 · Balance 34,366 Row 2 · 2026-03-09 · Sale · Disposed 17,900 · Balance 16,466 F1: Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.210 to $68.195. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-03-09 · Sale · Disposed 2,100 · Balance 14,366 F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.210 to $68.320. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-03-10 · Exercise / conversion · Acquired 1,546 · Balance 15,912 Row 5 · 2026-03-10 · Sale · Disposed 8,857 · Balance 7,055 F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.520 to $67.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $33.51 · Expires 2033-11-01 | Direct | 69,224 |
Reported balance
After 2026-03-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-09 · Exercise / conversion · Disposed 20,000 · Balance 69,224 F4: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was November 1, 2023. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $33.51 · Expires 2033-11-01 | Direct | 67,678 |
Reported balance
After 2026-03-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-10 · Exercise / conversion · Disposed 1,546 · Balance 67,678 F4: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was November 1, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.210 to $68.195. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.210 to $68.320. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.520 to $67.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was November 1, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2026 Filed Mar 10, 2026 23:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,546 | $33.51 Strike: $33.51 | $51,806.46 |
DisclosureSEC source: 0001159036-26-000033 · wk-form4_1773184732.xml · derivative · entry 7 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,678 Underlying: Common Stock · 1,546 shares Expires 2033-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was November 1, 2023. Read SEC document |
| March 10, 2026 Filed Mar 10, 2026 23:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 8,857 | $67.64 | $599,087.48 |
DisclosureSEC source: 0001159036-26-000033 · wk-form4_1773184732.xml · nonDerivative · entry 5 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,055 F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.520 to $67.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 10, 2026 Filed Mar 10, 2026 23:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,546 | $33.51 | $51,806.46 |
DisclosureSEC source: 0001159036-26-000033 · wk-form4_1773184732.xml · nonDerivative · entry 4 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 23:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $33.51 Strike: $33.51 | $670,200.00 |
DisclosureSEC source: 0001159036-26-000033 · wk-form4_1773184732.xml · derivative · entry 6 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,224 Underlying: Common Stock · 20,000 shares Expires 2033-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was November 1, 2023. Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 23:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 2,100 | $68.25 | $143,329.20 |
DisclosureSEC source: 0001159036-26-000033 · wk-form4_1773184732.xml · nonDerivative · entry 3 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,366 F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.210 to $68.320. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 23:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 17,900 | $67.75 | $1,212,742.90 |
DisclosureSEC source: 0001159036-26-000033 · wk-form4_1773184732.xml · nonDerivative · entry 2 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,466 F1 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.210 to $68.195. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 23:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $33.51 | $670,200.00 |
DisclosureSEC source: 0001159036-26-000033 · wk-form4_1773184732.xml · nonDerivative · entry 1 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 2,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000031 · wk-form4_1771975140.xml · derivative · entry 3 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,998 Underlying: Common Stock · 2,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,037 | $70.98 | $73,606.26 |
DisclosureSEC source: 0001159036-26-000031 · wk-form4_1771975140.xml · nonDerivative · entry 2 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,366 F1 · shares: The reported disposition of 1,037 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 2,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000031 · wk-form4_1771975140.xml · nonDerivative · entry 1 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 14,751 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000017 · wk-form4_1770862890.xml · derivative · entry 4 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,751 Underlying: Common Stock · 14,751 shares Expires not disclosed F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 2,403 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000017 · wk-form4_1770862890.xml · derivative · entry 3 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,886 Underlying: Common Stock · 2,403 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 13,047 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000017 · wk-form4_1770862890.xml · derivative · entry 2 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,047 Underlying: Common Stock · 13,047 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 14,047 | $0.00 Strike: $80.48 | $0.00 |
DisclosureSEC source: 0001159036-26-000017 · wk-form4_1770862890.xml · derivative · entry 1 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,047 Underlying: Common Stock · 14,047 shares Expires 2036-02-09 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| November 01, 2025 Filed Dec 19, 2025 22:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 9,326 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-25-000075 · wk-form4_1766183980.xml · derivative · entry 3 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,651 Underlying: Common Stock · 9,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| November 01, 2025 Filed Dec 19, 2025 22:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,263 | $65.19 | $277,904.97 |
DisclosureSEC source: 0001159036-25-000075 · wk-form4_1766183980.xml · nonDerivative · entry 2 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,737 F1 · shares: The reported disposition of 4,263 shares represents the shares that were withheld and sold by the issuer as payment for tax withholding obligations. Read SEC document |
| November 01, 2025 Filed Dec 19, 2025 22:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 9,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-25-000075 · wk-form4_1766183980.xml · nonDerivative · entry 1 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2025 Filed Oct 6, 2025 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 3,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002090209-25-000005 · form4-10062025_091000.xml · derivative · entry 2 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,625 Underlying: Common Stock · 3,625 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| October 03, 2025 Filed Oct 6, 2025 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 9,031 | $0.00 Strike: $68.98 | $0.00 |
DisclosureSEC source: 0002090209-25-000005 · form4-10062025_091000.xml · derivative · entry 1 Caudill Cortney · CIK 0002090209 · SVP, CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,031 Underlying: Common Stock · 9,031 shares Expires 2035-10-03 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.